Protagonist Therapeutics Reports Granting of Inducement Awards

Rhea-AI Summary

Protagonist Therapeutics (Nasdaq: PTGX) granted inducement equity awards on August 17, 2026 to two newly hired employees under its Amended and Restated Inducement Plan. The grants comprise options to purchase an aggregate 5,675 shares at an exercise price of $155.10 and RSUs for 1,500 shares, with four-year vesting schedules. The awards were approved by the compensation committee as material inducements in line with Nasdaq Rule 5635(c)(4).

Protagonist describes itself as a discovery-through-late-stage biopharmaceutical company. Its oral peptide ICOTYDE, licensed to a Johnson & Johnson company, launched in the U.S. in March 2026 for plaque psoriasis and is in Phase 3 for multiple immune indications, while rusfertide, licensed to Takeda, has an NDA under FDA priority review for polycythemia vera.

Positive

• Inducement grants align new hires with 5,675 options and 1,500 RSUs vesting over four years
• ICOTYDE launched in U.S. March 2026 for moderate-to-severe plaque psoriasis in adults and pediatric patients 12+
• ICOTYDE in multiple Phase 3 programs for psoriatic arthritis, ulcerative colitis and Crohn's disease
• Rusfertide NDA under FDA priority review for treatment of polycythemia vera

Negative

• None.

Market Context

The prior inducement-award announcements produced positive 24-hour reactions, including 6.73% on Jul...

Analysis

The prior inducement-award announcements produced positive 24-hour reactions, including 6.73% on July 16. That record contrasts with the neutral grant terms; recent insider net selling and an effective S-3ASR shelf were additional context.

Key Figures

Employees receiving awards: 2 employees Stock options: 5,675 shares Restricted stock units: 1,500 shares +4 more

7 metrics

Employees receiving awards 2 employees August 17, 2026 grant

Stock options 5,675 shares Aggregate inducement awards

Restricted stock units 1,500 shares Aggregate inducement awards

Option exercise price $155.10 per share Equal to the August 17, 2026 closing price

Option vesting period 4 years 25% vests on the first anniversary; remainder monthly thereafter

Initial option vesting 25% Vests on the first anniversary of each employee's hire date

Nasdaq rule Rule 5635(c)(4) Material inducement to employment

Historical Context

5 past events · Latest: Aug 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 05	Earnings report	Positive	+6.5%	Q2 license revenue, net income, and cash increased on collaboration economics.
Aug 04	Inducement awards	Neutral	+1.1%	Two hires received options and RSUs under the inducement plan.
Jul 16	Inducement awards	Neutral	+6.7%	Three hires received options and RSUs under the inducement plan.
Jul 01	Inducement awards	Neutral	+5.2%	Three new employees received options and RSUs under the inducement plan.
Jun 16	Inducement awards	Neutral	+0.7%	Three new employees received stock options and RSUs with four-year vesting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior inducement-award announcements were followed by positive 24-hour price reactions despite the announcements being operational and dilution-related.

Key Terms

restricted stock units, inducement plan, nda, priority review

4 terms

restricted stock units financial

"options to purchase 5,675 shares and restricted stock units (RSUs) to acquire 1,500 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

inducement plan financial

"under the Protagonist Therapeutics Amended and Restated Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

nda regulatory

"An NDA for rusfertide for the treatment of polycythemia vera"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

priority review regulatory

"for the treatment of polycythemia vera is under priority review with the FDA"

Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

The new employees received, in the aggregate, options to purchase 5,675 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 1,500 shares of Protagonist Therapeutics common stock. The exercise price of the options is $155.10, which is equal to the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on August 17, 2026. The shares subject to each option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of each employee's date of hire and the remainder vesting in equal monthly installments over three years thereafter. One-fourth of the shares underlying the RSUs will vest annually over a four-year period. The awards were approved by the compensation committee of the Company's board of directors and were granted as a material inducement to each employee entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE^™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE, launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceuticals. An NDA for rusfertide for the treatment of polycythemia vera is under priority review with the FDA. The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.

More information on Protagonist, its pipeline drug candidates and its clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577

Media Relations Contact

Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1

View the original press release on ACCESS Newswire

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

FAQ

What inducement awards did Protagonist Therapeutics (PTGX) grant on August 17, 2026?

Protagonist Therapeutics granted stock options for 5,675 shares and RSUs for 1,500 shares to two new employees. According to the company, these equity awards were issued under its Inducement Plan as material inducements to employment, consistent with Nasdaq Marketplace Rule 5635(c)(4).

What is the exercise price and vesting schedule for the new PTGX stock options?

The new Protagonist options have an exercise price of $155.10, equal to the August 17, 2026 Nasdaq closing price. According to the company, 25% vest on the first hire-date anniversary, with the remaining 75% vesting in equal monthly installments over the following three years.

How do the new Protagonist Therapeutics (PTGX) RSUs vest for the recent hires?

The RSUs granted to the two new Protagonist employees vest over four years. According to the company, one-fourth of the shares underlying the RSUs will vest annually, aligning long-term employee incentives with shareholder interests over the full vesting period.

What is ICOTYDE and what stage is it at for Protagonist Therapeutics (PTGX)?

ICOTYDE is a targeted oral peptide that blocks the Interleukin-23 receptor. According to Protagonist, it launched in the U.S. in March 2026 for moderate-to-severe plaque psoriasis and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease.

What is the status of Protagonist Therapeutics' rusfertide program with the FDA?

Rusfertide is a first-in-class hepcidin mimetic peptide discovered by Protagonist and licensed to Takeda. According to the company, a New Drug Application for rusfertide in polycythemia vera is currently under priority review by the U.S. Food and Drug Administration.

What therapeutic pipeline beyond ICOTYDE and rusfertide does Protagonist Therapeutics (PTGX) report?

Protagonist reports additional clinical and preclinical programs targeting validated pathways. According to the company, these include an oral IL-17 antagonist peptide, obesity-focused dual and triple agonists, an oral hepcidin functional mimetic, and recently announced IL-4 and amylin programs.